Skip to main content
Adocia logo

Adocia — Investor Relations & Filings

Ticker · ADOC ISIN · FR0011184241 LEI · 969500ZL79KYH9PTYP78 PA Real estate activities
Open in API
Filings indexed 826 across all filing types
Latest filing 2014-02-14 Declaration of Voting R…
Country FR France
Listing PA ADOC

About Adocia

https://www.adocia.com

Adocia is a clinical-stage biotechnology company that specializes in developing innovative treatments for metabolic diseases, with a primary focus on diabetes and obesity. The company's core expertise is the development of novel formulations of approved peptides, proteins, and metabolic hormones, such as insulin, to improve their therapeutic efficacy. Adocia leverages proprietary technology platforms to create a pipeline of specialty products. Its research also extends to novel cell therapy approaches, including an immunoprotective scaffold for cell delivery. The company's business model involves advancing its product candidates to clinical proof-of-concept before licensing them to partners for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Information relative au nombre d'actions et de droits de vote en date du 31 janvier 2014' and explicitly references Article L.233-8 II du Code de Commerce and article 223-16 du Règlement Général de l'Autorité des Marchés Financiers. It provides a table detailing the total number of shares and voting rights (gross and net) as of a specific date (January 31, 2014). This content directly relates to the disclosure of share capital structure and voting rights, which aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' (DVA) category, as it reports the official count of voting rights.
2014-02-14 French
Share buybacks / Liquidity contracts Information related to liquidity contracts
Regulatory Filings Classification · 1% confidence The document is a press release detailing the status of a liquidity agreement (share and cash balances) as of December 31, 2013. It does not represent a full financial report, nor is it a report publication announcement. It is a specific regulatory disclosure regarding the company's liquidity account activity, which falls under the category of general regulatory announcements and compliance filings. H2 2013
2014-01-20 English
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Capital/Financing Update Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and details the status of a liquidity contract (contrat de liquidité) as of December 31, 2013, comparing it to the previous reporting date (June 30, 2013). This is a periodic update concerning financial arrangements, specifically related to share trading/market making, which often falls under regulatory disclosure requirements. Since it is a press release providing specific financial/contractual status updates rather than a full financial report (like 10-K or IR) or a management discussion (MDA), and it relates to market operations, it is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the liquidity contract is viewed as a financing tool. Given the context of reporting on a specific contractual arrangement's status periodically, RNS is the most appropriate general regulatory fallback, as it is not a standard earnings release (ER) or interim report (IR). The length (under 5,000 characters) suggests it is an announcement rather than the full underlying report.
2014-01-20 French
Communicated under the obligation to provide permanent information / Other communications
Investor Presentation Classification · 1% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and details specific corporate news: the granting of two patents related to their BioChaperone® technology in Japan and the US. This type of announcement, focusing on a specific, timely corporate event (patent grants, clinical trial updates, business development), is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release announcing specific, non-financial-result-focused news (patents), it is not an ER (which focuses on financial results highlights) or an IR (Interim Report). It is a specific corporate update. Given the options, this is best classified as a general announcement or regulatory filing. Since it is a press release announcing a specific corporate event (patent grant), and not a formal regulatory report like a 10-K or IR, the most appropriate general category is Regulatory Filing (RNS), as it serves as a public disclosure of material information. However, if the focus is strictly on the content type (patent/IP news), it doesn't fit perfectly into the defined categories other than RNS or potentially LTR (Legal/IP related), but RNS is the standard catch-all for press releases not covered elsewhere. Given the context of a press release announcing IP news, RNS is the safest classification.
2014-01-13 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Investor Presentation Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces specific corporate news: the granting of patents in Japan and the US related to their BioChaperone® PDGF treatment for diabetic foot ulcers. This type of announcement, detailing specific operational or intellectual property achievements, is typically classified as a general regulatory announcement or press release that doesn't fit into the core financial reporting categories (like 10-K, ER, or IR). Since it is a formal announcement of a business development (patent grants) and not a full financial report, a management change, or a dividend notice, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous official announcements. The document length (8798 chars) is substantial, but the content is purely informational/news-based rather than a formal regulatory filing like a 10-K or IR. It is not an Earnings Release (ER) as it does not contain period financial results, nor is it an Investor Presentation (IP). Therefore, RNS is the best fit.
2014-01-13 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Information relative au nombre d'actions et de droits de vote en date du 31 décembre 2013' (Information relative to the number of shares and voting rights as of December 31, 2013). It explicitly references French commercial code (Article L.233-8 II du Code de Commerce) and AMF regulations (article 223-16 du Règlement Général de l'Autorité des Marchés Financiers). The content is a monthly breakdown of the total number of shares and voting rights. This type of mandatory disclosure regarding the capital structure and voting rights is typically classified as a regulatory filing or a specific announcement related to capital changes, but given the options, it most closely relates to changes in share structure or general regulatory reporting. Since it is a formal disclosure of the total number of shares and voting rights, it is a specific regulatory disclosure. It is not a dividend announcement (DIV), a general earnings release (ER), or a management change (MANG). It is a periodic report on the capital structure. While it could potentially fall under RNS (Regulatory Filings) as a fallback, the content is highly specific to share capital and voting rights, which often triggers specific reporting requirements. However, none of the codes perfectly match 'Share Capital/Voting Rights Report'. Given the options, 'SHA' (Share Issue/Capital Change) is the closest fit as it deals directly with the number of shares and voting rights, even if it's a periodic update rather than a single transaction announcement. Alternatively, since it is a mandatory regulatory disclosure not covered by other specific codes (like 10-K, ER, etc.), RNS is a strong candidate. Given the focus on the total number of shares and voting rights, SHA is more descriptive of the content than the general RNS fallback. I will classify it as SHA, as it is a formal report on the capital structure.
2014-01-10 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.